



**HAL**  
open science

## **Role of AmiA in the morphological transition of Helicobacter pylori and in immune escape.**

Catherine Chaput, Chantal Ecobichon, Nadège Cayet, Stephen E Girardin,  
Catherine Werts, Stéphanie Guadagnini, Marie-Christine Prévost, Dominique  
Mengin-Lecreulx, Agnès Labigne, Ivo G Boneca

► **To cite this version:**

Catherine Chaput, Chantal Ecobichon, Nadège Cayet, Stephen E Girardin, Catherine Werts, et al..  
Role of AmiA in the morphological transition of Helicobacter pylori and in immune escape.. PLoS  
Pathogens, 2006, 2 (9), pp.e97. 10.1371/journal.ppat.0020097 . pasteur-00139174

**HAL Id: pasteur-00139174**

**<https://hal-pasteur.archives-ouvertes.fr/pasteur-00139174>**

Submitted on 29 Mar 2007

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Role of AmiA in the Morphological Transition of *Helicobacter pylori* and in Immune Escape

Catherine Chaput<sup>1</sup>, Chantal Ecobichon<sup>1</sup>, Nadège Cayet<sup>2</sup>, Stephen E. Girardin<sup>3</sup>, Catherine Werts<sup>4</sup>, Stéphanie Guadagnini<sup>2</sup>, Marie-Christine Prévost<sup>2</sup>, Dominique Mengin-Lecreulx<sup>5</sup>, Agnès Labigne<sup>1</sup>, Ivo G. Boneca<sup>1\*</sup>

**1** Unité de Pathogénie Bactérienne des Muqueuses, Institut Pasteur, Paris, France, **2** Plate-Forme de Microscopie Électronique, Institut Pasteur, Paris, France, **3** Groupe Avenir, INSERM U389, Unité de Pathogénie Microbienne Moléculaire, Institut Pasteur, Paris, France, **4** Groupe Immunité Innée et Signalisation, Institut Pasteur, Paris, France, **5** Enveloppes Bactériennes et Antibiotiques, UMR 8619 CNRS, Université Paris-Sud, Orsay, France

**The human gastric pathogen *Helicobacter pylori* is responsible for peptic ulcers and neoplasia. Both in vitro and in the human stomach it can be found in two forms, the bacillary and coccoid forms. The molecular mechanisms of the morphological transition between these two forms and the role of coccoids remain largely unknown. The peptidoglycan (PG) layer is a major determinant of bacterial cell shape, and therefore we studied *H. pylori* PG structure during the morphological transition. The transition correlated with an accumulation of the *N*-acetyl-D-glucosaminyl- $\beta$ (1,4)-*N*-acetylmuramyl-L-Ala-D-Glu (GM-dipeptide) motif. We investigated the molecular mechanisms responsible for the GM-dipeptide motif accumulation, and studied the role of various putative PG hydrolases in this process. Interestingly, a mutant strain with a mutation in the *amiA* gene, encoding a putative PG hydrolase, was impaired in accumulating the GM-dipeptide motif and transforming into coccoids. We investigated the role of the morphological transition and the PG modification in the biology of *H. pylori*. PG modification and transformation of *H. pylori* was accompanied by an escape from detection by human Nod1 and the absence of NF- $\kappa$ B activation in epithelial cells. Accordingly, coccoids were unable to induce IL-8 secretion by AGS gastric epithelial cells. *amiA* is, to our knowledge, the first genetic determinant discovered to be required for this morphological transition into the coccoid forms, and therefore contributes to modulation of the host response and participates in the chronicity of *H. pylori* infection.**

Citation: Chaput C, Ecobichon C, Cayet N, Girardin SE, Werts C, et al. (2006) Role of AmiA in the morphological transition of *Helicobacter pylori* and in immune escape. PLoS Pathog 2(9): e97. DOI: 10.1371/journal.ppat.0020097

## Introduction

*Helicobacter pylori* is a human pathogen with a unique niche: the stomach. The presence of this bacterium is always associated with chronic gastritis, and less often with severe duodenal ulcers, gastric adenocarcinoma, or mucosa-associated lymphoid tissue lymphoma. *H. pylori* has the interesting ability to convert from bacillary to coccoid forms. The coccoid forms appear in stationary phase and can also be induced under stress conditions, for example, following modification of pH, O<sub>2</sub> tension, or temperature [1,2], or exposure to antibiotics such as amoxicillin [3,4]. However, there is still controversy regarding the biological role of this form. Both forms are commonly observed in the human stomach [5,6]. Coccoids are viable but noncultivable, and this has led to the suggestion that the coccoid form is the persisting form, allowing *H. pylori* to spread between human hosts. Coccoid forms contain a reasonable quantity of ATP [7] and an active respiratory chain [8–10]; it is also viable as assessed by viability staining [11–14]. Various proteins (including VacA and CagA) and activities (for example, urease activity) are detectable, but it is not clear whether there is any de novo protein synthesis [15]. Attempts to revert coccoid bacteria to spiral under laboratory conditions have failed so far. In contrast, several groups have reported colonization of mice with coccoid bacteria and have subsequently isolated spiral bacteria from their stomachs, indicating that under certain conditions coccoids may revert back to spiral bacteria [16–19].

Despite interest in this subject, little is known about the

process of morphological transition into coccoid forms. Proteome and transcriptome analyses have failed to identify proteins involved in the transition [7,20–23]. The *cdrA* gene has been implicated in coccoid formation [24], but these results are controversial because the *cdrA* gene is inactivated in several strains, including the two sequenced strains 26695 and J99. Hence, CdrA is unlikely to have a major role, if any, in coccoid formation. It is known, however, that the lipid composition of *H. pylori* changes substantially during the transition into coccoid forms [25].

One of the main determinants of bacterial shape is the peptidoglycan (PG) layer (for a recent review see [26]). Costa et al. [27] implicated a modification of the mureptide

**Editor:** Scott J. Hultgren, Washington University School of Medicine, United States of America

**Received:** December 27, 2005; **Accepted:** August 7, 2006; **Published:** September 22, 2006

**DOI:** 10.1371/journal.ppat.0020097

**Copyright:** © 2006 Chaput et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Abbreviations:** (anh)M, *N*-acetyl-anhydromuramic acid; GM-dipeptide, *N*-acetyl-D-glucosaminyl- $\beta$ (1,4)-*N*-acetylmuramyl-L-Ala-D-Glu; GM-tripeptide, *N*-acetyl-D-glucosaminyl- $\beta$ (1,4)-*N*-acetylmuramyl-L-Ala- $\gamma$ -D-Glu-*meso*-diaminopimelic acid; hNod1, human Nod1; hNod2, human Nod2; HPLC, high-pressure liquid chromatography; km, kanamycin; MIC, minimum inhibitory concentration; *meso*DAP, *meso*-diaminopimelic acid; mtz, metronidazole; PG, peptidoglycan; SEM, scanning electron microscopy; TEM, transmission electron microscopy

\* To whom correspondence should be addressed. E-mail: bonecai@pasteur.fr

## Synopsis

*Helicobacter pylori* is a human pathogen responsible for gastric diseases such as ulcers and gastric cancers. Despite the host's vigorous immune response, *H. pylori* is capable of persisting for decades in its human host. *H. pylori* is found in biopsies in two distinct forms, a spiral rod form and a coccoid form. Chaput et al. investigated the molecular mechanisms leading to the transition of *H. pylori* from a spiral rod-shaped organism to a coccoid organism. The morphological transition is accompanied by modifications of the bacterial cell wall peptidoglycan. The authors have identified the AmiA protein as essential for this morphological transition and modification of the cell wall peptidoglycan. Additionally, the authors show that the cell wall modifications and morphological transition allow these coccoid forms to escape detection by the immune system and therefore could participate in the persistence of *H. pylori* infection during the lifetime of its human host.

composition of *H. pylori* PG in the transition from the bacillary to the coccoid form: the *N*-acetyl-D-glucosaminyl- $\beta$ (1,4)-*N*-acetylmuramyl-L-Ala-D-Glu (GM-dipeptide) motif accumulated in the sacculus after 2 d of liquid culture. This motif lacks the diamino acid, *meso*-diaminopimelic acid (*meso*DAP), required for PG transpeptidation. Possibly, a change to a looser PG macromolecule could explain the shape transition of *H. pylori* from spiral to coccoid.

Here, we studied the genetic determinants involved in the accumulation of the GM-dipeptide motif. Several alternative mechanisms could explain this phenomenon (see Protocol S1 and Figure S2), and PG hydrolases could be involved. We describe the construction of a mutant strain with a mutation of the *amiA* gene—encoding a putative PG hydrolase—that is impaired in the accumulation of the GM-dipeptide motif; it is also defective in the transition from spiral bacteria into coccoid forms. We show that the phenotype of morphological transition and PG modification is associated with impaired sensing by the Nod1 pathway, impaired activation of NF- $\kappa$ B, and impaired cytokine production by AGS gastric epithelial cells. We thus identified a new mechanism for bacterial escape from the innate immune system.

## Results

### Accumulation of the GM-Dipeptide Motif in the PG of Various Strains of *H. pylori*

We purified and analyzed the PG from the sequenced strain 26695 and from the strain NCTC11637 used as a control. No major difference between chromatograms of the two strains was observed (Figures 1 and S1). Muropeptide composition analysis of *H. pylori* PG showed an accumulation of the GM-dipeptide motif in strain 26695 during the stationary phase, as previously observed in strain NCTC11637 (Figures 1 and S1; [27]). Interestingly, the accumulation of the GM-dipeptide (peak 4 in Figures 1 and S1) coincided with a decrease of *N*-acetyl-D-glucosaminyl- $\beta$ (1,4)-*N*-acetylmuramyl-L-Ala- $\gamma$ -D-Glu-*meso*DAP (GM-tripeptide) (peak 1).

We used a targeted approach to investigate the molecular mechanisms responsible for the accumulation of the GM-dipeptide motif (see Protocol S1 and Figure S2). We constructed mutants of *hp0087* (encoding a putative peptidase), *hp1118* (encoding a gamma-glutamyltranspeptidase), *hp0645* (encoding the lytic transglycosylase Slt), *hp1572*


(encoding the lytic transglycosylase MltD), and *hp0772* (encoding the putative *N*-acetylmuramoyl-L-alanine amidase AmiA). Detailed information for each gene and protein is available on the PyloriGene database (<http://genolist.pasteur.fr/PyloriGene/genome.cgi>). Only in the *amiA* mutant was the accumulation of GM-dipeptide impaired (peak 4 in Figures 1 and S3). The PG of this mutant contained less of this motif at 8 h, 24 h, and 48 h (about 1.9-, 2.3-, and 2.9-fold less, respectively) than the parental strain (Figure 1). The amount of GM-tripeptide (peak 1) remained stable between exponential and stationary phase. The residual amount of GM-dipeptide present in the PG of the *amiA* mutant is probably due to the decrease of MurE activity in stationary phase (Figure S4).

### Morphology of the *amiA* Mutant

We studied the morphology of the *amiA* mutant during the different growth stages using scanning electron microscopy (SEM) and after ruthenium red staining using transmission electron microscopy (TEM) to visualize PG in the periplasmic space (Figure 2). The *amiA* mutant was observed as very long bacterial chains of up to 30 bacteria per chain after 4 h of culture (Figure 2D and 2E), while the parental strain 26695 showed normal individual rod-shaped bacteria (Figure 2A). Sections stained with ruthenium red revealed completely formed septa in the *amiA* mutant (Figure 2G and 2H), indicating daughter cell separation was defective. The parental strain, 26695, showed rod, U, donut, and coccoid forms after 2 d, 1 wk, and 1 mo of culture (Figure 2B and 2C; unpublished data), while the *amiA* mutant remained in long chains of rod-shaped bacteria (Figure 2F). Far fewer *amiA* mutant cells were in coccoid forms after similar times of growth (Table 1). Therefore, the *amiA* mutant seems to be blocked both for cell separation and for the transition into coccoid forms.

### Complementation of the *amiA* Mutant

Next, we tried to complement the phenotype by introducing a wild-type *amiA* gene at a different locus, that of the *rdxA* gene (Figure S5). Disruption of the *rdxA* gene confers metronidazole (mtz) resistance to *H. pylori* [28]. However, the insertion of a copy of the *amiA* gene into the *rdxA* gene in the same orientation was lethal for *H. pylori*. When the *amiA* gene was inserted into the *rdxA* gene in the opposite orientation, transformants were obtained. PCR analysis showed two populations of transformants: (1) bacteria with *amiA* in *rdxA* and the wild-type *amiA* gene inactivated by the kanamycin (km) cassette (mtz<sup>R</sup>km<sup>R</sup> mutants), and (2) mutants with *amiA* in *rdxA* and with the wild-type *amiA* gene restored (mtz<sup>R</sup>km<sup>S</sup> mutants). Only the second type of mutants (mtz<sup>R</sup>km<sup>S</sup>) complemented the filamentation phenotype and restored the transition into coccoid forms. Hence, the observed phenotype could not be due to a secondary mutation. To eliminate the possibility of polar effects of the *amiA* mutant on the downstream gene, we also constructed a mutant of the downstream gene, *hp0771*. The *hp0771* mutant showed a normal bacillary form during the first day of culture, and the capacity to adopt the coccoid form. We quantified the proportions of bacillary and coccoid forms (Table 1): the *amiA* mutant was the only strain impaired in the transition into coccoid forms.



**Figure 1.** Muropeptide Profile of *H. pylori* PG

PG from parental strain 26695 (A) and its *amiA* isogenic mutant (B) were purified and digested with the muramidase M1 (mutanolysin). The generated muropeptides were separated by HPLC. The HPLC profiles show muropeptide composition after 8 h, 24 h, and 48 h of bacterial growth. Each peak structure was assigned by MALDI-TOF mass spectrometry and corresponds to a different muropeptide: (1) GM-tripeptide, (2) GM-tetrapeptide, (3) GM-tetrapeptide-glycine, (4) GM-dipeptide, and (5) GM-pentapeptide. Dimers were then eluted: (6) GM-tetrapeptide-tripeptide-MG, (7) GM-tetrapeptide-tetrapeptide-glycine-MG, (8) GM-tetrapeptide-tetrapeptide-MG, and (9) GM-tetrapeptide-pentapeptide-MG. Finally, anhydromuropeptides were eluted: (10) G(anh)M-pentapeptide, (11) and (12) G(anh)M-tetrapeptide-tripeptide-MG, (13) and (14) G(anh)M-tetrapeptide-tetrapeptide-MG, and (15) G(anh)M-tetrapeptide-pentapeptide-MG.

DOI: 10.1371/journal.ppat.0020097.g001

### Amoxicillin Effects

Some stress signals, including amoxicillin treatment, can induce the morphological transition into coccoid forms [4]. We investigated the response of the *amiA* mutant to amoxicillin. First, we determined the minimum inhibitory concentration (MIC) of amoxicillin: it was identical for the *amiA* mutant and the parental strain 26695 (0.06  $\mu\text{g/ml}$ ). After overnight culture, 10  $\mu\text{g/ml}$  amoxicillin was added to the medium, and after 3 h of antibiotic treatment, bacteria were observed using SEM. The *amiA* mutant formed chains of spherical bacteria (Figure 3), rod-shaped bacteria, and, most frequently, both rod-shaped and spherical bacteria. Thus, the impaired morphological transition is not an artifact and does not result from steric hindrance of bacterial chain formation (see Table 1 for quantification). Therefore, *AmiA* is required both for PG modifications and for the morphological transition.


### Epithelial Cell Response to *H. pylori* PG and Coccoid Forms

Having demonstrated that the transition into coccoid forms is a process controlled by *AmiA*, we investigated the biological role of the coccoid forms. The accumulation of the GM-dipeptide motif (Figure 1, peak 4) correlated with the almost disappearance of the GM-tripeptide motif (Figure 1, peak 1). These two muropeptides are the agonists of the human Nod2 (hNod2) and human Nod1 (hNod1) proteins, respectively [29]. Sensing of *H. pylori* PG by Nod1 is essential for the inflammatory response by gastric epithelial cells [30]. Therefore, the switch from being a hNod1 agonist to being a

hNod2 agonist during coccoid formation could affect the ability of gastric epithelial cells to detect *H. pylori* and to develop an inflammatory response.

NF- $\kappa$ B activation in HEK293T cells via stimulation by hNod1 and hNod2 was tested with digested PG extracted from the *amiA* mutant and the parental strain after 8 h and 48 h of growth (Figure 4A). Nod1 responses showed highest NF- $\kappa$ B activation with PG extracted after 8 h of growth and less activation with PG extracted at 48 h of growth, for both wild-type strains (26695 and NCTC11637). Thus, the activation decreased with decreasing abundance of the GM-tripeptide in *H. pylori* PG. For the *amiA* mutant, hNod1 responses were the same when cells were stimulated with PG extracted after 8 h or 48 h of growth, consistent with the unchanging GM-tripeptide content of the PG. Conversely, hNod2 responses revealed a higher NF- $\kappa$ B activation with PG extracted after 48 h of growth than with PG extracted after 8 h (Figure 4B). These results suggest that spiral bacteria preferentially induce NF- $\kappa$ B via hNod1 and coccoid bacteria via hNod2.

However, hNod2 (as hNod1) senses muropeptides and not polymeric PG; we therefore tested whether naturally occurring PG turnover products can stimulate hNod2. These products are mainly anhydromuropeptides generated by endogenous PG hydrolases called lytic transglycosylases. We compared the hNod2-dependent activation of NF- $\kappa$ B by *H. pylori* PG digested by a muramidase (M1) and a lytic transglycosylase (Slt70 from *Escherichia coli*). Figure S6 shows the chromatogram of the Slt70-digested PG of *H. pylori* and the structural assignment of each anhydromuropeptide. As



**Figure 2.** Morphologies of *H. pylori*

(A–F) SEM of *H. pylori* during exponential-phase growth (4 h of culture (A, D, and E) and after 1 wk of culture (B, C, and F) of the parental strain 26695 (A–C) and the *amiA* mutant (D–F).

(G and H) TEM sections of the *amiA* mutant after ruthenium staining. The *amiA* mutant is able to form a complete septum without final daughter cell separation. Chains of the *amiA* mutant contained up to 30–40 bacteria.

DOI: 10.1371/journal.ppat.0020097.g002

expected from our previous results [31], anhydromuropeptides were able to induce NF- $\kappa$ B in a Nod1-dependent manner (Figure 4C). Surprisingly, anhydromuropeptides were unable to induce NF- $\kappa$ B in a Nod2-dependent manner. To further investigate the structural basis of hNod2 sensing, we compared the Nod2-dependent activation of NF- $\kappa$ B by the GM-dipeptide and its anhydro derivative, G(anh)M-dipeptide ([anh]M indicates *N*-acetyl-anhydromuramic acid). The GM-dipeptide motif produced by *H. pylori* was detected via hNod2 in a dose-dependent manner. However, Nod2 did not sense the GanhM-dipeptide motif (Figure 4D). We conclude that PG turnover products are agonists of the Nod1 pathway [31], but are unable to induce the Nod2 pathway. Accordingly, rod-shaped *H. pylori* induced NF- $\kappa$ B in HEK293T cells and IL-8 production by gastric epithelial cells, but coccoid bacteria had no NF- $\kappa$ B or IL-8 stimulatory activities (Figure 4E and 4F). As epithelial cells do not respond to coccoid forms or to PG turnover products from coccoid forms, our study suggests that coccoid forms provide a route for immune escape for *H. pylori*.

## Discussion

Since the first observation of microbes, bacterial shape has been considered to be largely invariant and a characteristic feature of each species. It has therefore been used as a major taxonomic determinant. Nevertheless, several bacteria are known to change morphology during genetic developmental programs such as sporulation or asymmetric cell division. *H. pylori* undergoes morphological transition from spiral to coccoid. Previous attempts to identify specific markers or a dedicated genetic program involved in this morphological transition have been inconclusive [7,20–23]. Nevertheless, in 1999, Costa and colleagues correlated the morphological transition with a modification of *H. pylori* PG muropeptide composition [27], that is, the accumulation of the GM-dipeptide motif.

The PG layer is a major determinant of bacterial cell shape, so we felt that identifying the genetic determinants involved in the observed PG modification could help elucidate the morphological transition. There are several possible explanations for the accumulation of the GM-dipeptide motif (see


**Table 1.** Quantification of the Number of Coccoid Forms

Strain	Days of Growth	Percent Coccoids <sup>a</sup>	Number of Counted Bacteria
26695	1 wk	55.79%	699
26695 <i>amiA</i> <sup>-</sup>	1 wk	6.26%	405
26695 771::Tn3-km	1 wk	57.24%	449
26695 + amoxicillin	3–4 h <sup>b</sup>	56.64%	685
26695 <i>amiA</i> <sup>-</sup> + amoxicillin	3–4 h <sup>b</sup>	32.60%	1,003

<sup>a</sup>Includes U and donut forms. For the *amiA* mutant, counts of bacteria correspond to individual bacteria that composed each chain.

<sup>b</sup>Time of exposure to amoxicillin after 18 h of growth without antibiotic.

DOI: 10.1371/journal.ppat.0020097.t001



**Figure 3.** Effect of Amoxicillin on *H. pylori* Morphology

SEM of *H. pylori* strain 26695 (A and B) and its isogenic *amiA* mutant (C and D) grown without amoxicillin (A and C) and after 3–4 h exposure to 10 µg/ml amoxicillin (B and D). Amoxicillin treatment of the *amiA* mutant bypasses the requirement of *amiA* for the morphological transition, indicating that absence of coccoid forms was not due to sterical hindrance of the bacterial chains.

DOI: 10.1371/journal.ppat.0020097.g003


Protocol S1 and Figure S2). It could result from a defect in precursor synthesis in the cytoplasm due to (1) a decrease of MurE activity blocking PG precursor synthesis at the step where *meso*DAP is added to the uracyl diphosphate-M-dipeptide, (2) insufficient *meso*DAP to allow synthesis of precursors, or (3) the presence of a carboxy/endopeptidase, cleaving between the second and the third amino acid residue. This carboxy/endopeptidase activity could be in either the cytoplasm (cleaving PG precursors with more than two amino acid residues in the stem peptide) or the periplasm (directly cleaving macromolecular PG). We also considered the potential roles of the annotated PG hydrolases Slt, MltD, and AmiA in this process [31]. Protocol S1 summarizes the various hypotheses and the data supporting or inconsistent with each of them. We identified the *amiA* gene as necessary for the PG modification. The *amiA* mutant was impaired in the transition to coccoid forms. This is, to our knowledge, the first identification of a genetic determinant required for the morphological transition of *H. pylori*, and also directly implicates PG modification in determining bacterial morphology. To our knowledge, this is the first description of a putative PG hydrolase directly involved in maintenance of bacterial cell shape. *N*-acetylmuramoyl-L-alanine amidases contribute to the separation of daughter cells in *E. coli* [32], but three genes encoding amidases had to be deleted from *E. coli* to observe a changed phenotype, whereas in *H. pylori* inactivation of a single gene was sufficient to produce a comparable filamentation phenotype.

Interestingly, the accumulation of GM-dipeptide motif (Figure 1, peak 4) coincided with a proportional decrease of the GM-tripeptide motif (Figure 1, peak 1). In the *amiA*

mutant, the proportion of GM-tripeptide remained stable and the amounts of the GM-dipeptide were very low. No significant changes were observed for the other monomeric mucopeptides. This is consistent with the activity of a periplasmic carboxy/endopeptidase that recognizes the  $\gamma$ -D-glutamyl-*meso*-diaminopimelic acid bond.

The AmiA protein is structured as a bimodular protein: a signal peptide followed by an N-terminal domain without homology to any sequences in the NCBI non-redundant database (amino acids 1–177), a linker peptide of variable length composed of KKEIP repeats (amino acids 178–190), and an C-terminal domain (amino acids 191–440) homologous to CwlU and CwlV, which are predicted to have an *N*-acetylmuramoyl-L-alanine amidase activity [33]. PG amidases cleave the PG in the periplasm between the *N*-acetylmuramic acid residue and the first amino acid residue of the peptide moiety, L-alanine. However, the amidase activity of AmiA and its closest homologs has never been confirmed, so it is plausible that AmiA has a carboxy/endopeptidase activity. Alternatively, AmiA might be bifunctional, with an N-terminal carboxy/endopeptidase activity and a C-terminal amidase activity. It is also possible that AmiA has an amidase activity that is unable to cleave stem peptides with less than three amino acid residues such as the human serum amidase or peptidoglycan recognition protein L [34]. This would lead to the elimination of stem peptides with three to five amino acid residues, and consequently the accumulation of GM-dipeptides. We are currently studying the biochemistry of the AmiA protein to resolve this issue.

We have shown that the morphological transition is regulated by AmiA. In its absence, the transition can be



**Figure 4.** hNod1- and hNod2-Dependent Activation of NF- $\kappa$ B by *H. pylori* PG

(A and B) PG samples from strain NCT11637, strain 26695, and the isogenic *amiA* mutant prepared after 8 h and 48 h of growth, were digested with M1 (mutanolysin) to generate muopeptides and used to stimulate hNod1 (A) and hNod2 (B).

(C and D) PG samples were also digested with recombinant Slt70 from *E. coli* to generate anhydromuopeptides, used to stimulate hNod1 and hNod2, and compared to M1-generated muopeptides (C). hNod1 and hNod2 agonists were used at 10 nM and PGs at 0.3  $\mu$ g/ml. Finally, purified GM-dipeptide and its anhydrous derivative G(anh)M-dipeptide were also tested for their ability to stimulate hNod2 (D).

(E) *H. pylori* at different growth stages (spiral versus coccoid) and different multiplicity of infection (MOI) were used to stimulate the HEK293T cells, and NF- $\kappa$ B activation was determined.

(F) The same experiment as in (E) was performed with the AGS gastric epithelial cell line, and IL-8 secretion was determined. TNF- $\alpha$  (20 ng/ml) was used as a positive control.

MDP, muramyl-dipeptide; NS, nonstimulated; TriDAP, L-alanyl-D-glutamyl-mesoDAP.

DOI: 10.1371/journal.ppat.0020097.g004

induced by treatment with amoxicillin, a  $\beta$ -lactam antibiotic. Exposure to amoxicillin bypasses the requirement for the AmiA protein, suggesting that one of the other determinants might be a penicillin-binding protein. Amoxicillin preferentially targets *H. pylori* PBP2 [4], a homolog of *E. coli* PBP2. A PBP2 conditional mutant of *E. coli* becomes spherical at nonpermissive temperature, [35] and, consequently, PBP2 is believed to drive lateral PG synthesis.

The role of PG metabolism in the transition into coccoid forms suggests this might be a regulated process rather than a random degeneration of *H. pylori* cells. Therefore, coccoid forms might be important in *H. pylori* physiology. Consistent with this, Segal and colleagues showed that coccoid forms are able to translocate CagA—one of the major virulence factors and the only known effector protein of the *H. pylori* type IV secretion system—and induce cellular changes [36]. Coccoid forms express other virulence factors, including the func-

tional CagA. We showed that coccoid forms modulate NF- $\kappa$ B activation. The morphological transition of *H. pylori* is accompanied by a decrease in the abundance of the GM-tripeptide motif, the hNod1 agonist, and this decrease minimizes the activation of NF- $\kappa$ B (via hNod1) in HEK293T cells and abolishes IL-8 induction in gastric epithelial cells. Thus, the coccoid forms might allow the bacteria to escape or modulate the host response and thereby to persist in the human stomach. To our knowledge, this would be a previously undescribed mechanism for pathogens to respond to a chronic inflammatory response.

Nevertheless, coccoid forms may potentially stimulate epithelial cells via hNod2, in particular in an inflamed mucosa. Indeed, the hNod2 pathway can be induced by TNF- $\alpha$  and INF- $\gamma$  in an NF- $\kappa$ B-dependent manner [37,38]. During a chronic infection of the gastric mucosa, coccoid forms of *H. pylori* would preferentially stimulate NF- $\kappa$ B via



hNod2. However, hNod2 (as hNod1) senses muropeptides instead of polymeric PG. Muropeptides can be generated either by host lysozyme or by *H. pylori* endogenous lytic transglycosylases such as Slt. While lysozyme is abundant in paneth cells, it is almost absent from the mucus layer [39], where *H. pylori* preferentially resides [40]. Furthermore, like Gram-negative bacteria in general, *H. pylori* is insensitive to lysozyme's activity. Muropeptides generated by the endogenous lytic transglycosylases such as G(anh)M-dipeptide (Figure 4D) are not sensed by the hNod2 pathway. Hence, coccoid forms are unlikely to be seen by the host, suggesting these could function as a mechanism of escape from and modulation of the host's innate immune system. *Campylobacter jejuni* also undergoes morphological transition into coccoid forms. *C. jejuni* usually causes acute gastroenteritis, but a recent study has associated long-term intestinal colonization of patients by *C. jejuni* with the onset of intestinal mucosa-associated lymphoid tissue lymphoma [41]. Possibly, coccoid forms of *C. jejuni* are similarly involved in establishing chronic infection.

In conclusion, we report the *amiA* gene as the first genetic determinant to our knowledge discovered that is involved in the transition of spiral bacteria into coccoid forms. Further characterization of AmiA should be of interest in determining how *H. pylori* regulates the transition from bacillary into coccoid forms and for investigations of the physiological importance, in vitro and in vivo, of this particular bacterial form.

## Materials and Methods

**Bacteria, cells, and growth conditions.** *E. coli* MC1061 [42] and DH5 $\alpha$  were used as hosts for the construction and preparation of plasmids. They were cultivated in Luria Bertani solid or liquid medium supplemented as appropriate with spectinomycin (100  $\mu$ g/ml) or kanamycin (40  $\mu$ g/ml) or both. *H. pylori* strain 26695 [43] was used to construct mutants. PG was extracted from strains 26695 and NCTC11637. *H. pylori* was grown microaerobically at 37 °C on blood agar plates or in liquid medium consisting of brain-heart infusion (Oxoid, <http://www.oxoid.com>) with 0.2%  $\beta$ -cyclodextrin (Sigma-Aldrich, <http://www.sigmaaldrich.com>) supplemented with antibiotic-antifungal mix [44]. *H. pylori* mutants were selected on 20  $\mu$ g/ml kanamycin. HEK293T cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. Prior to transfection, HEK293T cells were seeded into 24-well plates at a density of 10<sup>5</sup> cells/ml as described previously [45].

**Construction of mutants and complementation.** Genes were disrupted as described previously [46]. *H. pylori* mutants were constructed by allelic exchange after transformation with suicide plasmids or PCR products carrying the gene of interest interrupted by a nonpolar cassette *aphA-3* [46] or mini*Tn3*-km transposon and selected on kanamycin. PCRs were used to confirm that correct allelic exchange occurred. Gene constructions were sequenced to ensure sequence fidelity. All reagents, enzymes, and kits were used according to manufacturers' recommendations. Midiprep (HiSpeed Plasmid Midi Kit) and DNA extraction kits (QIAamp DNA extraction kit) were purchased from Qiagen (<http://www.qiagen.com>).

The plasmid pILL2000 was used to construct the *amiA* mutant. pILL570 carrying ORF *hp0772* (*amiA* gene) was used as the template for an Expand High Fidelity PCR (Amersham, <http://www.amershambiosciences.com>) with oligonucleotides 772-1 (5'-gaugau-gauggtaccaggatttaactcataagtc-3', in which the underlined sequence corresponds to a *KpnI* site) and 772-2 (5'-aucaucaucggatccaacagc-cagcgattgatcgtctctaac-3', in which the underlined sequence corresponds to a *BamHI* site). PCR products were digested with *BamHI* (Amersham) and *KpnI* (Amersham) and ligated (T4 DNA ligase, Amersham) with the *aphA-3* nonpolar cassette digested with the same endonucleases.

Complementation experiments were done by insertion of the *amiA* gene in the *rdxA* locus, either in the same orientation or in the reverse orientation. The *amiA* mutant was used as a recipient for the suicide

plasmid or PCR products for complementation. Constructs were made as follows. For the same orientation, the construct was made by three-time PCR [47]. Each of three fragments and the final fragment used for transformation were obtained by Expand High Fidelity PCR. First, three fragments were obtained: (i) a 300-bp fragment corresponding to the 5'-end of *rdxA* obtained with oligonucleotides 954F (5'-atgaaattttggatcaagaaaaag-3') and CC772in954-1 (5'-CA-CAAGCACtacaattaacctcattgaaatagatgtgcgctgc-3', with the capital letters corresponding to the sequence hybridizing with the 5'-end of the *amiA* gene); (ii) a 1,320-bp fragment corresponding to the *amiA* gene obtained with oligonucleotides CCrbs772 (5'-gagggttaattgt-tagtctgtg-3') and CC772stop (5'-ctaatactcttctgtaagaaac-3'); and (iii) a 300-bp fragment corresponding to the 3'-end of *rdxA* obtained with oligonucleotides 954Rev (5'-tcacaaccaagtaactgcaaac-3') and CC772in954-2 (5'-GTTTCTTCAGCAAGAATGATTAGtacctggagg-gaataatcaatgctatcgctgtgggg-3', with the capital letters corresponding to the sequence hybridizing with the 3'-end of the *amiA* gene). The final PCR product was obtained by using a mixture of these three fragments as a template and oligonucleotides 954F and 954Rev.

For the reverse orientation, the pILL570-*rdxA* plasmid was used as the template for an Expand High Fidelity PCR (Amersham) with oligonucleotides 954-2KpnI (5'-cgggtaccctactgcaaaatctctatccg-3', in which the underlined sequence corresponds to a *KpnI* site) and 954-1BamHI (5'-cgcggatcctggtgtaaccaactcgtggg-3', in which the underlined sequence corresponds to a *BamHI* site). The *amiA* gene was amplified using the following primers: 772-compl-1Bis (5'-cgggtacc-gagggttaattgtatgctgtgaggttaggg-3', in which the underlined sequence corresponds to a *BamHI* site) and 772-compl-2Bis (5'-cgggtaccctaatcattctgctgaaaaactatcaatgcc-3', in which the underlined sequence corresponds to a *KpnI* site). PCR products were digested with *BamHI* (Amersham) and *KpnI* (Amersham) and ligated (T4 DNA ligase, Amersham).

The *hp0087* mutant was obtained following natural transformation of *H. pylori* with a construct made of three PCR products [47]. Each of three fragments and a final fragment used for transformation were obtained by Expand High Fidelity PCR. First, three fragments were obtained: (i) a 300-bp fragment corresponding to the 5'-end of HP0087 obtained with oligonucleotides 87-NotI (5'-ataagaatcgccgc-cATGcgtttttctgttagtttc-3') and 87-in1 (5'-GTTAGTACCCGGG-TACTgactttcatatctagccatgggg-3', with the capital letters corresponding to the sequence hybridizing with the 5'-end of the *aphA-3* gene); (ii) a 850-bp fragment corresponding to the *aphA-3* cassette; and (iii) a 300-bp fragment corresponding to the 3'-end of HP0087 obtained with oligonucleotides 87-EcoRI (5'-ggaatTCAattg-catttaagggcttg-3', with the capital letters corresponding to the stop codon of HP0087) and 87-in2 (5'-TACCTGGAGGGAATAATGgactat-catcctaaaaacgcc-3', with the capital letters corresponding to the sequence hybridizing with the 3'-end of the *aphA-3* gene). The final PCR product was obtained by using a mixture of these three fragments as a template and oligonucleotides 87-NotI and 87-EcoRI.

Gamma-glutamyltranspeptidase (*hp1118*) and *hp0771* mutants were obtained by gene interruption with mini*Tn3*; there are no genes downstream from *hp0771* and *hp1118* with the same direction of transcription. The interruption was generated in *E. coli* DH5 $\alpha$  by insertion of mini*Tn3* into plasmids carrying either *hp0771* or *hp1118* (C. Ecobichon, C. Chevalier, and A. Labigne, unpublished data). Plasmids carrying the insertions were checked by PCR and used to transform *H. pylori* 26695. Mutants were validated by PCR analysis. The *hp1118* mutant was also tested for the absence of gamma-glutamyltranspeptidase activity as previously described [48].

**Peptidoglycan extraction and analysis.** Liquid cultures of *H. pylori* parental strain and isogenic mutant strains were stopped after various times of growth and chilled in an ice-ethanol bath. The crude murein sacculus was immediately extracted in boiling sodium dodecyl sulphate (4% final concentration). Purification steps and high-pressure liquid chromatography (HPLC) analyses were as described previously [49]. Recombinant lytic transglycosylase Slt70 was purified as previously described [50]. Mutanolysin (M1)- or Slt70-digested samples (M1 from Sigma-Aldrich) were analyzed by HPLC on a Hypersil ODS18 reverse-phase column (250  $\times$  4.6 mm, 3- $\mu$ m particle size) with a methanol (HPLC grade, Fisher Scientific, <http://www.fisherscientific.com>) gradient from 0% to 15% in sodium phosphate buffer (pH 4.3 to 5.0). Chromatograms were obtained by monitoring at 206 nm. Each peak was collected, desalted, and identified by MALDI-MS as described previously [51].

**Quantification of MurE activity.** Bacteria were collected by centrifugation (3,000 g, 20 min, 4 °C) from 400 ml of culture after 8 h, 24 h, and 48 h of *H. pylori* growth. The bacterial pellets were washed with potassium phosphate buffer (20 mM, 0.5 mM magnesium dichloride and 2-mercaptoethanol [pH 7.4]), and resuspended in



the same buffer. The cells were sonicated with a Branson sonifier (<http://www.sonifier.com>) at 20W per minute until the lysate was clear. The samples were dialysed twice against the same buffer. MurE activity in these crude extracts was determined as described previously [52].

**Electron microscopy.** Bacteria were washed with PBS (pH 7.4) and stained with ruthenium red or used directly for SEM. For ruthenium red staining, bacteria were prefixed with 2.5% glutaraldehyde, in 0.075% ruthenium red, and 0.1 M cacodylate buffer for 1 h. Samples were rinsed with 0.1 M cacodylate buffer and post-fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer for 2 h. They were washed in water three times and then dehydrated in a series of ethanol concentrations. Finally, the samples were embedded in Spurr, and ultrathin sections were made. Grids were viewed by TEM with a JEOL Jem 1010 microscope (<http://www.jeol.com>).

For SEM, samples were washed in PBS, prefixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer for 30 min, and then rinsed in 0.2 M cacodylate buffer. After post-fixation in 1% osmium tetroxide (in 0.2 M cacodylate buffer), bacteria were dehydrated in a series of ethanol concentrations. Specimens were critical-point dried using carbon dioxide, then coated with gold and examined with a JEOL JSM-6700F SEM.

**MIC.** To determine the MIC for amoxicillin, suspensions of *H. pylori* estimated to contain  $10^8$  bacteria/ml ( $OD_{600nm}$  of 0.1) were serially diluted and grown on plates containing various concentrations of amoxicillin. The MIC was defined as the amoxicillin concentration leading to a decrease of three log of colony-forming units per milliliter as compared to growth without amoxicillin.

**Expression plasmids, transient transfections, and NF- $\kappa$ B activation assays.** The expression plasmid for FLAG-tagged hNod1 was from Gabriel Nuñez (University of Michigan Medical School, Ann Arbor, Michigan, United States) and has been described previously [53]. The expression plasmid for hNod2 was from Gilles Thomas (Fondation Jean Dausset/CEPH, Paris, France). HEK293T cells were used for transfections as described previously [45]. Synergistic activation of NF- $\kappa$ B by PGs, muramyl peptides, and related compounds in cells overexpressing Nod1 or Nod2 was studied as described by Inohara et al. [54]. Briefly, HEK293T cells were transfected overnight with 1 ng of hNod1 or 1 ng of hNod2 plus 75 ng of Ig luciferase reporter plasmid. PG samples (0.1  $\mu$ g/ml) were digested with 0.25  $\mu$ g/ $\mu$ l mutanolysin. At the same time, 0.3  $\mu$ g of PG preparations or 10 pmol of muramyl peptides were added to the cell culture medium, and synergistic NF- $\kappa$ B-dependent luciferase activation was measured after 24 h of co-incubation. NF- $\kappa$ B-dependent luciferase assays were performed in duplicate, and data reported represent at least three independent experiments. Data were standardized with positive controls: *N*-acetylmuramic acid-dipeptide for hNod2 and *N*-acetylmuramic acid-tripeptide for hNod1. hNod1 and hNod2 were activated with *H. pylori* PG (0.3  $\mu$ g/ml) digested with M1 or Slt70 as previously described [29].

## Supporting Information

**Figure S1.** Chromatograms of *H. pylori* 26695 and NCTC11637 Strains after Two Different Times of Culture (8 h and 48 h)

These results are consistent with previous observations [27] and with the results obtained with strain 26695 (Figure 1).

Found at DOI: 10.1371/journal.ppat.0020097.sg001 (305 KB PPT).

**Figure S2.** Schematic Representation of Hypotheses Concerning the Accumulation of GM-Dipeptide in the PG of *H. pylori* during the Transition from Spiral into Coccioid Forms

This accumulation might be generated by the increase in the cytoplasm of PG precursors carrying a dipeptide (then incorporated into periplasmic PG) or by carboxy/endopeptidase activity present in the periplasm (represented by red scissors). The modification of the

PG precursor pool in cytoplasm might be due to (i) insufficient *meso*DAP preventing normal biosynthesis or (ii) a decrease of MurE activity, which is then the limiting step in the biosynthesis of precursors and leads to an increase of dipeptide precursor.

Found at DOI: 10.1371/journal.ppat.0020097.sg002 (174 KB PPT).

**Figure S3.** Chromatograms of *H. pylori* 26695 Isogenic Mutants for *slt*, *mltD*, *hp0087*, and *hp1118* after 48 h of Culture

The four mutants accumulate the GM-dipeptide at 48 h of growth to the same extent as the parental strain 26695 (see Figure 1).

Found at DOI: 10.1371/journal.ppat.0020097.sg003 (273 KB PPT).

**Figure S4.** MurE Activity in *H. pylori* Strain 26695 and *amiA* Mutant after 8 h, 24 h, and 48 h of Growth

For each time point, the specific MurE activity was measured in crude protein extracts. The specific activity is expressed in nanomoles per minute per milligram.

Found at DOI: 10.1371/journal.ppat.0020097.sg004 (40 KB PPT).

**Figure S5.** Schematic Representation of the *amiA* Locus and *rdxA* Gene

The *amiA* gene was inactivated with a nonpolar kanamycin cassette. Complementation studies involved inserting the *amiA* gene into the *rdxA* locus. Note that *amiA* was introduced without a promoter, and, therefore, expression of the *amiA* gene is driven by the *rdxA* locus endogenous promoters. HP0771 was inactivated by a mini*Tn3*-km transposon, since the downstream gene is oriented in the opposite direction.

Found at DOI: 10.1371/journal.ppat.0020097.sg005 (44 KB PPT).

**Figure S6.** *H. pylori* PG Was Digested with Recombinant Slt70 from *E. coli* and Analyzed by HPLC

Each peak was collected and the structure was determined by MALDI-TOF mass spectrometry. Peaks 1 to 9 correspond to the following anhydromuropeptides: (1) G(anh)M-tripeptide, (2) G(anh)M-tetrapeptide, (3) G(anh)M-tetraglycine-peptide, (4) G(anh)M-dipeptide, (5) G(anh)M-pentapeptide, (6) G(anh)M-tri-tetra-(anh)MG, (7) G(anh)M-tetra-tetraglycine-(anh)MG, (8) G(anh)M-tetra-tetra-(anh)MG, and (9) G(anh)M-penta-tetra-(anh)MG.

Found at DOI: 10.1371/journal.ppat.0020097.sg006 (66 KB PPT).

**Protocol S1.** Supplementary Data

Found at DOI: 10.1371/journal.ppat.0020097.sd001 (79 KB DOC).

## Acknowledgments

We thank Christophe Burucoa for helpful discussions and references concerning coccioid forms.

**Author contributions.** CC, AL, and IGB conceived and designed the experiments. CC, CE, NC, SEG, CW, SG, DML, and IGB performed the experiments. CC, MCP, AL, and IGB analyzed the data. CW and DML contributed reagents/materials/analysis tools. CC and IGB wrote the paper.

**Funding.** CC was supported by a fellowship from the French Ministry (Ministère de l'Éducation Nationale, de la Recherche et de la Technologie). The research was supported by Institut Pasteur grant PTR153 and an Action Concertée Incitative Microbiology grant from the Ministère Chargé de la Recherche (INSERM number MIC 0321). IGB was supported by a fellowship of the Fundação para a Ciência e Tecnologia (Portugal) and a Bourse Roux from the Institut Pasteur, and is an INSERM research associate.

**Competing interests.** The authors have declared that no competing interests exist.

## References

1. Tominaga K, Hamasaki N, Watanabe T, Uchida T, Fujiwara Y, et al. (1999) Effect of culture conditions on morphological changes of *Helicobacter pylori*. *J Gastroenterol* 34 (Suppl 11): 28–31.
2. Donelli G, Matarrese P, Fiorentini C, Dainelli B, Taraborelli T, et al. (1998) The effect of oxygen on the growth and cell morphology of *Helicobacter pylori*. *FEMS Microbiol Lett* 168: 9–15.
3. Berry V, Jennings K, Woodnutt G (1995) Bactericidal and morphological effects of amoxicillin on *Helicobacter pylori*. *Antimicrob Agents Chemother* 39: 1859–1861.
4. DeLoney CR, Schiller NL (1999) Competition of various beta-lactam

- antibiotics for the major penicillin-binding proteins of *Helicobacter pylori*: Antibacterial activity and effects on bacterial morphology. *Antimicrob Agents Chemother* 43: 2702–2709.
5. Noach LA, Rolf TM, Tytgat GN (1994) Electron microscopic study of association between *Helicobacter pylori* and gastric and duodenal mucosa. *J Clin Pathol* 47: 699–704.
6. Chan WY, Hui PK, Leung KM, Chow J, Kwok F, et al. (1994) Coccioid forms of *Helicobacter pylori* in the human stomach. *Am J Clin Pathol* 102: 503–507.
7. Nilsson HO, Blom J, Abu-Al-Soud W, Ljungh AA, Andersen LP, et al. (2002) Effect of cold starvation, acid stress, and nutrients on metabolic activity of *Helicobacter pylori*. *Appl Environ Microbiol* 68: 11–19.

8. Cellini L, Robuffo I, Di Campli E, Di Bartolomeo S, Taraborelli T, et al. (1998) Recovery of *Helicobacter pylori* ATCC43504 from a viable but not culturable state: Regrowth or resuscitation? *APMIS* 106: 571–579.
9. Cole SP, Cirillo D, Kagnoff MF, Guiney DG, Eckmann L (1997) Coccoid and spiral *Helicobacter pylori* differ in their abilities to adhere to gastric epithelial cells and induce interleukin-8 secretion. *Infect Immun* 65: 843–846.
10. Gribbon LT, Barer MR (1995) Oxidative metabolism in nonculturable *Helicobacter pylori* and *Vibrio vulnificus* cells studied by substrate-enhanced tetrazolium reduction and digital image processing. *Appl Environ Microbiol* 61: 3379–3384.
11. Adams BL, Bates TC, Oliver JD (2003) Survival of *Helicobacter pylori* in a natural freshwater environment. *Appl Environ Microbiol* 69: 7462–7466.
12. Cole SP, Kharitonov VF, Guiney DG (1999) Effect of nitric oxide on *Helicobacter pylori* morphology. *J Infect Dis* 180: 1713–1717.
13. Shirai M, Kakada J, Shibata K, Morshed MG, Matsushita T, et al. (2000) Accumulation of polyphosphate granules in *Helicobacter pylori* cells under anaerobic conditions. *J Med Microbiol* 49: 513–519.
14. Taneera J, Moran AP, Hynes SO, Nilsson HO, Al-Soud W, et al. (2002) Influence of activated charcoal, porcine gastric mucin and beta-cyclodextrin on the morphology and growth of intestinal and gastric *Helicobacter* spp. *Microbiology* 148: 677–684.
15. Mizoguchi H, Fujioka T, Kishi K, Nishizono A, Kodama R, et al. (1998) Diversity in protein synthesis and viability of *Helicobacter pylori* coccoid forms in response to various stimuli. *Infect Immun* 66: 5555–5560.
16. Aleljung P, Nilsson HO, Wang X, Nyberg P, Morner T, et al. (1996) Gastrointestinal colonisation of BALB/cA mice by *Helicobacter pylori* monitored by heparin magnetic separation. *FEMS Immunol Med Microbiol* 13: 303–309.
17. Cellini L, Allocati N, Angelucci D, Iezzi T, Di Campli E, et al. (1994) Coccoid *Helicobacter pylori* not culturable in vitro reverts in mice. *Microbiol Immunol* 38: 843–850.
18. She FF, Lin JY, Liu JY, Huang C, Su DH (2003) Virulence of water-induced coccoid *Helicobacter pylori* and its experimental infection in mice. *World J Gastroenterol* 9: 516–520.
19. Wang X, Sturegard E, Rupar R, Nilsson HO, Aleljung PA, et al. (1997) Infection of BALB/c A mice by spiral and coccoid forms of *Helicobacter pylori*. *J Med Microbiol* 46: 657–663.
20. Bumann D, Habibi H, Kan B, Schmid M, Goosmann C, et al. (2004) Lack of stage-specific proteins in coccoid *Helicobacter pylori* cells. *Infect Immun* 72: 6738–6742.
21. Nilsson I, Utt M, Nilsson HO, Ljungh A, Wadstrom T (2000) Two-dimensional electrophoretic and immunoblot analysis of cell surface proteins of spiral-shaped and coccoid forms of *Helicobacter pylori*. *Electrophoresis* 21: 2670–2677.
22. Figueroa G, Faundez G, Troncoso M, Navarrete P, Toledo MS (2002) Immunoglobulin G antibody response to infection with coccoid forms of *Helicobacter pylori*. *Clin Diagn Lab Immunol* 9: 1067–1071.
23. Monstein HJ, Jonasson J (2001) Differential virulence-gene mRNA expression in coccoid forms of *Helicobacter pylori*. *Biochem Biophys Res Commun* 285: 530–536.
24. Takeuchi H, Shirai M, Akada JK, Tsuda M, Nakazawa T (1998) Nucleotide sequence and characterization of *cdra*, a cell division-related gene of *Helicobacter pylori*. *J Bacteriol* 180: 5263–5268.
25. Shimomura H, Hayashi S, Yokota K, Oguma K, Hirai Y (2004) Alteration in the composition of cholesteryl glucosides and other lipids in *Helicobacter pylori* undergoing morphological change from spiral to coccoid form. *FEMS Microbiol Lett* 237: 407–413.
26. Cabeen MT, Jacobs-Wagner C (2005) Bacterial cell shape. *Nat Rev Microbiol* 3: 601–610.
27. Costa K, Bacher G, Allmaier G, Dominguez-Bello MG, Engstrand L, et al. (1999) The morphological transition of *Helicobacter pylori* cells from spiral to coccoid is preceded by a substantial modification of the cell wall. *J Bacteriol* 181: 3710–3715.
28. Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Zanten SJ, Berg DE, et al. (1998) Metronidazole resistance in *Helicobacter pylori* is due to null mutations in a gene (*rdxA*) that encodes an oxygen-insensitive NADPH nitroreductase. *Mol Microbiol* 28: 383–393.
29. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, et al. (2003) Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. *Science* 300: 1584–1587.
30. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, et al. (2004) Nod1 responds to peptidoglycan delivered by the *Helicobacter pylori* cag pathogenicity island. *Nat Immunol* 5: 1166–1174.
31. Boneca IG, de Reuse H, Epinat JC, Pupin M, Labigne A, et al. (2003) A revised annotation and comparative analysis of *Helicobacter pylori* genomes. *Nucleic Acids Res* 31: 1704–1714.
32. Heidrich C, Templin MF, Ursinus A, Merdanovic M, Berger J, et al. (2001) Involvement of N-acetylmuramyl-L-alanine amidases in cell separation and antibiotic-induced autolysis of *Escherichia coli*. *Mol Microbiol* 41: 167–178.
33. Ishikawa S, Kawahara S, Sekiguchi J (1999) Cloning and expression of two autolysin genes, *cwIU* and *cwIV*, which are tandemly arranged on the chromosome of *Bacillus polymyxa* var. *colistinus*. *Mol Gen Genet* 262: 738–748.
34. Wang ZM, Li X, Cocklin RR, Wang M, Wang M, et al. (2003) Human peptidoglycan recognition protein-L is an N-acetylmuramoyl-L-alanine amidase. *J Biol Chem* 278: 49044–49052.
35. Spratt BG, Boyd A, Stoker N (1980) Defective and plaque-forming lambda transducing bacteriophage carrying penicillin-binding protein-cell shape genes: Genetic and physical mapping and identification of gene products from the *lip-dacA-rodA-bbpA-leuS* region of the *Escherichia coli* chromosome. *J Bacteriol* 143: 569–581.
36. Segal ED, Falkow S, Tompkins LS (1996) *Helicobacter pylori* attachment to gastric cells induces cytoskeletal rearrangements and tyrosine phosphorylation of host cell proteins. *Proc Natl Acad Sci U S A* 93: 1259–1264.
37. Gutierrez O, Pipaon C, Inohara N, Fontalba A, Ogura Y, et al. (2002) Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. *J Biol Chem* 277: 41701–41705.
38. Rosenstiel P, Fantini M, Brautigam K, Kuhbacher T, Waetzig GH, et al. (2003) TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. *Gastroenterology* 124: 1001–1009.
39. Saito H, Kasajima T, Masuda A, Imai Y, Ishikawa M (1988) Lysozyme localization in human gastric and duodenal epithelium. An immunocytochemical study. *Cell Tissue Res* 251: 307–313.
40. Hidaka E, Ota H, Hidaka H, Hayama M, Matsuzawa K, et al. (2001) *Helicobacter pylori* and two ultrastructurally distinct layers of gastric mucous cell mucins in the surface mucous gel layer. *Gut* 49: 474–480.
41. Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, et al. (2004) Immunoproliferative small intestinal disease associated with *Campylobacter jejuni*. *N Engl J Med* 350: 239–248.
42. Casadaban MJ, Cohen SN (1980) Analysis of gene control signals by DNA fusion and cloning in *Escherichia coli*. *J Mol Biol* 138: 179–207.
43. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, et al. (1997) The complete genome sequence of the gastric pathogen *Helicobacter pylori*. *Nature* 388: 539–547.
44. Bury-Mone S, Thiberge JM, Contreras M, Maitournam A, Labigne A, et al. (2004) Responsiveness to acidity via metal ion regulators mediates virulence in the gastric pathogen *Helicobacter pylori*. *Mol Microbiol* 53: 623–638.
45. Girardin SE, Tournebise R, Mavris M, Page AL, Li X, et al. (2001) CARD4/ Nod1 mediates NF-kappaB and JNK activation by invasive *Shigella flexneri*. *EMBO Rep* 2: 736–742.
46. Skouloubris S, Thiberge JM, Labigne A, De Reuse H (1998) The *Helicobacter pylori* UreI protein is not involved in urease activity but is essential for bacterial survival in vivo. *Infect Immun* 66: 4517–4521.
47. Derbise A, Lesic B, Dacheux D, Ghigo JM, Carniel E (2003) A rapid and simple method for inactivating chromosomal genes in *Yersinia*. *FEMS Immunol Med Microbiol* 38: 113–116.
48. Chevalier C, Thiberge JM, Ferrero RL, Labigne A (1999) Essential role of *Helicobacter pylori* gamma-glutamyltranspeptidase for the colonization of the gastric mucosa of mice. *Mol Microbiol* 31: 1359–1372.
49. Glauner B (1988) Separation and quantification of muropeptides with high-performance liquid chromatography. *Anal Biochem* 172: 451–464.
50. Stenbak CR, Ryu JH, Leulier F, Pili-Floury S, Parquet C, et al. (2004) Peptidoglycan molecular requirements allowing detection by the *Drosophila* immune deficiency pathway. *J Immunol* 173: 7339–7348.
51. Antignac A, Rousselle JC, Namane A, Labigne A, Taha MK, et al. (2003) Detailed structural analysis of the peptidoglycan of the human pathogen *Neisseria meningitidis*. *J Biol Chem* 278: 31521–31528.
52. Dementin S, Bouhss A, Auger G, Parquet C, Mengin-Lecreux D, et al. (2001) Evidence of a functional requirement for a carbamoylated lysine residue in MurD, MurE and MurF synthetases as established by chemical rescue experiments. *Eur J Biochem* 268: 5800–5807.
53. Inohara N, Koseki T, del Peso L, Hu Y, Yee C, et al. (1999) Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. *J Biol Chem* 274: 14560–14567.
54. Inohara N, Ogura Y, Chen FF, Muto A, Nunez G (2001) Human Nod1 confers responsiveness to bacterial lipopolysaccharides. *J Biol Chem* 276: 2551–2554.